Jump to Navigation
Home

Main menu

  • Home
  • News
  • Markets Map
  • Topics
  • Data
  • Comments
  • Images
  • Blog
  • About

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • Discussions
  • Now You Can 3D Print Your Own Invisibility Cloak
  • North Korea 'launches missiles'
  • Ex Amazon Employee: Google Is 'A Threat 'To...
  • Switzerland close to deal in U.S. tax dispute: finance...
  • S Korea says North Korea fires 3 short-range missiles
  • Facebook's IPO, one year on
  • Astronaut From Space Station Feels Dizzy, Horrible, And...
  • Switzerland close to deal in U.S. tax dispute: finance...
  • These Are The International Social Networks Closing In On...
  • IRS Chief Refuses To Name The Boneheads Who Targeted Tea...

    Drug research quality drops, but costs keep rising

    Thu, 07/28/2011 - 10:41 EDT - Bizmology
    • Buzzworthy
    • Cetero research
    • contract research
    • Covance
    • CRO
    • false data
    • falsified results
    • FDA
    • misconduct
    • Outsourcing
    • Pharmaceuticals
    • PPD
    • Quintiles
    • R&D
    • RDF10
    • research costs

    The FDA has cited a small contract research firm, Cetero Research, for falsifying drug testing results. This news comes on top of reports that pharmaceutical research costs are steadily rising. Put [...]

    • Original article
    • Login or register to post comments
     

    Related

    • The FDA Has A Huge Problem With Scientific Misconduct

      This week, we reported that the Food and Drug Administration left medicines on the market for years after discovering they were approved based on fraudulent studies by Cetero Research, which did testing for drug companies worldwide.

    • Drugs Based On Bad Research Will Stay On The Market

      On the morning of May 3, 2010, three agents of the Food and Drug Administration descended upon the Houston office of Cetero Research, a firm that conducted research for drug companies worldwide.

    • Contract research firm Cetero seeks bankruptcy protection

      (Reuters) - Contract research firm Cetero filed for bankruptcy protection early on Monday, court documents show, months after the U.S. drug regulator put the company on notice for faking documents and manipulating drug samples. In July last year, the U.S. Food and Drug Administration (FDA) said two 2010 inspections, an internal company investigation and a third-party audit uncovered "significant instances of misconduct and violations" at a Cetero facility in Houston. The Cary, North Carolina-based firm does early-phase clinical research and bioanalytics for a number of drugmakers. ...

    • FDA Knew Lab Committed Research Fraud, Approved Drug They Tested Anyway

      (efkjr79)

    • Drugs Approved Due To Fraudulent Research Still On Market, FDA Shrugs

      (Charles Williams)

    • Contract research firm Cetero seeks bankruptcy protection

      (Reuters) - Contract research firm Cetero filed for bankruptcy protection early on Monday, court documents show, months after the U.S.

    • Pfizer’s ‘virtual’ drug trial could reshape R&D processes

      Ever thought about answering one of those “Do you suffer from migraines?” or “Got bunions?” clinical trial ads, but just haven’t had the time or energy to enroll?

    • FDA Investigates Deaths in Connection With Recalled J&J Medicines: Biotech's Latest Mishaps

      The Burrill Report submits: The U.S. Food and Drug Administration is investigating reports of complications with dozens of recalled children's medications made by Johnson & Johnson (JNJ), including 30 deaths, but so far no direct link has been found, according to a Congressional staff report, Reuters reported. “At this time, FDA is not aware of any child being harmed by taking one of the recalled products,” according to the report.

    • Contract Research (CROs): On the Brink of Recovery

      Morningstar submits: by Lauren Migliore

    • Immunodiagnostic Systems sees profits surge and secures FDA clearance for new automated assays

      Immunodiagnostic Systems (LON:IDH), the company that makes diagnostic testing kits for the clinical and research markets, has received clearance from the US Food and Drug Administration (FDA) for two new automated assays to be sold in the US. The new product additions complement IDS’s existing automated products offered on its IDS-iSYS system in the US, which is the company’s fastest growing market. The news comes as IDS reported a 35 percent rise in sales to £50.2 million in the 12 months to the end of March, with pre-tax profits up 51 percent to £16.6 million.

    Latest

    Ex Amazon Employee: Google Is 'A Threat 'To Amazon's Cloud (AMZN, GOOG)
    Ex Amazon Employee: Google Is 'A Threat...
    BERNANKE TO GRADUATES: 'Success And Satisfaction Will Not Come From Mastering A Fixed Body Of Knowledge'
    BERNANKE TO GRADUATES: 'Success And...

    User login

    • Create new account
    • Request new password
    • Click on the icon to sign in with your social network login or enter your Bullfax.com login

    Our Blog

    • Aviva steps up drive for cost cuts
    • Food Demand, JM Financial, UK Startups Incubator and Sina in Our News for Today 05/17/2013
    • Budget black hole at heart of George Osborne’s finances

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 1667.47 1.02% FTSE: 6723.06 0.52% Nikk.: 15138.12 0.67% DAX: 8398.00 0.33% HSI: 23082.68 0.17% FX: EUR/GBP: 1.1821 USD/EUR: 1.2833 JPY/USD: 103.165 Commodities: Gold: 1360.15

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • Discussions